-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the state's supervision of pharmaceutical companies has been continuously increasing
.
Especially since the implementation of the "Measures for Unannounced Inspection of Pharmaceuticals and Medical Devices", the normalization of unannounced inspections has become more and more obvious
.
It is worth noting that, in the context of the current reform and upgrading of the medical system and the fact that on-site inspections of production sites have become the new normal of drug supervision, unannounced inspections of the pharmaceutical industry in many provinces and cities have obviously begun to become more frequent.
Just recently, many provinces have A series of inspection results have been released consecutively, among which a batch of pharmaceutical companies have been ordered to rectify and a batch have been fined
.
On September 22, the unannounced inspection notice issued by the Guizhou Provincial Drug Administration showed that during the unannounced inspection of Guizhou Yibai Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Yibei Pharmaceutical") in June this year, it was found that the company had 7 For this defect, he was ordered to rectify within a time limit
.
In fact, this is not the first time Yibai Pharmaceutical has been notified of a violation
.
According to a review, the company and its executives have been publicly condemned and criticized for many times
.
In addition, the notification also showed that during the unannounced inspection conducted by the Guizhou Provincial Drug Administration in June this year, 9 pharmaceutical companies including Guizhou Braun and its subsidiaries were also found to have defects on the spot and were ordered to rectify within a time limit
.
Specifically, Guizhou Bailing Enterprise Group Pharmaceutical Co.
, Ltd.
found 7 defects on site, and Guizhou Province Bailing Enterprise Group Zhengxin Pharmaceutical Co.
, Ltd.
found 11 defects on site
.
On August 9, the Anhui Provincial Food and Drug Administration issued two supervision and inspections on the circulation of medicines and the production supervision and inspection of Chinese herbal medicines
.
The information notice showed that in July, the Fourth Branch of Anhui Province inspected 8 pharmaceutical companies, all of which took the form of non-notification
.
According to the inspection results, one of them had 2 general defects and was required to rectify within a time limit
.
Prior to this, on August 6, the Anhui Provincial Food and Drug Administration actually issued the third phase of the 2021 drug quality announcement
.
According to the announcement, the current sampling information involved 1322 batches of products from 392 sampling units and 430 pharmaceutical manufacturers
.
A total of 3 production companies that were found to be unqualified in the inspection results
.
According to the production batch number, the "inferior drug" Apocynum venetum of one of the investigated pharmaceutical companies is expected to be produced in 2020.
By then, the company is expected to receive heavy fines in accordance with the new Drug Administration Law
.
Generally speaking, medicines are special commodities and are related to the health and safety of the human body.
With the tightening of industry supervision, especially under the implementation of the revised "Drug Administration Law", the industry generally believes that in the future, the country and even local governments will treat drugs and pharmaceutical companies.
The supervision of will continue to be strengthened
.
What should pharmaceutical companies do in the face of such a situation? The industry believes that, as a pharmaceutical company, it is necessary to build a safe production line of defense and standardize operations in order to go further
.
Specifically, what pharmaceutical companies have to do is to pay attention to the unannounced inspections in a timely manner, reflect on themselves from the unannounced inspection reports of other companies, and make continuous improvements
.
And in the production of medicines, don't take any chances anymore, stick to quality and standardize production
.
Under such an operation, no matter how strict and frequent future supervision is, it will not have much impact on pharmaceutical companies
.
.
Especially since the implementation of the "Measures for Unannounced Inspection of Pharmaceuticals and Medical Devices", the normalization of unannounced inspections has become more and more obvious
.
It is worth noting that, in the context of the current reform and upgrading of the medical system and the fact that on-site inspections of production sites have become the new normal of drug supervision, unannounced inspections of the pharmaceutical industry in many provinces and cities have obviously begun to become more frequent.
Just recently, many provinces have A series of inspection results have been released consecutively, among which a batch of pharmaceutical companies have been ordered to rectify and a batch have been fined
.
On September 22, the unannounced inspection notice issued by the Guizhou Provincial Drug Administration showed that during the unannounced inspection of Guizhou Yibai Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Yibei Pharmaceutical") in June this year, it was found that the company had 7 For this defect, he was ordered to rectify within a time limit
.
In fact, this is not the first time Yibai Pharmaceutical has been notified of a violation
.
According to a review, the company and its executives have been publicly condemned and criticized for many times
.
In addition, the notification also showed that during the unannounced inspection conducted by the Guizhou Provincial Drug Administration in June this year, 9 pharmaceutical companies including Guizhou Braun and its subsidiaries were also found to have defects on the spot and were ordered to rectify within a time limit
.
Specifically, Guizhou Bailing Enterprise Group Pharmaceutical Co.
, Ltd.
found 7 defects on site, and Guizhou Province Bailing Enterprise Group Zhengxin Pharmaceutical Co.
, Ltd.
found 11 defects on site
.
On August 9, the Anhui Provincial Food and Drug Administration issued two supervision and inspections on the circulation of medicines and the production supervision and inspection of Chinese herbal medicines
.
The information notice showed that in July, the Fourth Branch of Anhui Province inspected 8 pharmaceutical companies, all of which took the form of non-notification
.
According to the inspection results, one of them had 2 general defects and was required to rectify within a time limit
.
Prior to this, on August 6, the Anhui Provincial Food and Drug Administration actually issued the third phase of the 2021 drug quality announcement
.
According to the announcement, the current sampling information involved 1322 batches of products from 392 sampling units and 430 pharmaceutical manufacturers
.
A total of 3 production companies that were found to be unqualified in the inspection results
.
According to the production batch number, the "inferior drug" Apocynum venetum of one of the investigated pharmaceutical companies is expected to be produced in 2020.
By then, the company is expected to receive heavy fines in accordance with the new Drug Administration Law
.
Generally speaking, medicines are special commodities and are related to the health and safety of the human body.
With the tightening of industry supervision, especially under the implementation of the revised "Drug Administration Law", the industry generally believes that in the future, the country and even local governments will treat drugs and pharmaceutical companies.
The supervision of will continue to be strengthened
.
What should pharmaceutical companies do in the face of such a situation? The industry believes that, as a pharmaceutical company, it is necessary to build a safe production line of defense and standardize operations in order to go further
.
Specifically, what pharmaceutical companies have to do is to pay attention to the unannounced inspections in a timely manner, reflect on themselves from the unannounced inspection reports of other companies, and make continuous improvements
.
And in the production of medicines, don't take any chances anymore, stick to quality and standardize production
.
Under such an operation, no matter how strict and frequent future supervision is, it will not have much impact on pharmaceutical companies
.
